macular degeneration/edema

FIELD OF THE INVENTION This invention relates to a method and system for using a calibrated retinoscope and parallel light technique to estimate the reflection of melanin particles in the retina to detect macular degeneration prior to physical symptoms. BACKGROUND OF THE INVENTION In the Western

FIELD OF THE INVENTION This invention relates to a method and system for using a calibrated retinoscope and parallel light technique to estimate the reflection of melanin particles in the retina to detect macular degeneration prior to physical symptoms. BACKGROUND OF THE INVENTION In the Western

BACKGROUND OF THE INVENTION Macular edema is swelling within the retina within the critically important central visual zone at the posterior pole of the eye. An accumulation of fluid within the retina tends to distract the neural elements from one another and from their local blood supply, creating

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a new use of a hydantoin derivative, in particular, (2S,4S)-6-fluoro-2',5'-dioxospiro [chroman-4,4'-imidazolidine]-2-carboxamide, as a pharmaceutical preparation. 2. Description of the Related Art The number of

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a new use of a hydantoin derivative, in particular, (2S,4S)-6-fluoro-2',5'-dioxospiro [chroman-4,4'-imidazolidine]-2-carboxamide, as a pharmaceutical preparation. 2. Description of the Related Art The number of

FIELD OF THE INVENTION The present disclosure generally relates to compositions and methods for the prevention, stabilization and/or treatment of macular edema, in particular that results from central retinal vein occlusion (CRVO), branch retinal vein occlusion (BRVO), age related macular

FIELD OF THE INVENTION The present invention is directed generally to methods of regulating VE-cadherin and claudin gene expression in retinal tissue by applying to such tissue norrin protein; and in particular, to produce additional cellular production of VE-cadherin and claudin-5 in retinal

FIELD OF THE INVENTION The present invention is directed generally to methods of regulating VE-cadherin and claudin gene expression in retinal tissue by applying to such tissue norrin protein; and in particular, to produce additional cellular production of VE-cadherin and claudin-5 in retinal

FIELD OF THE INVENTION The present invention relates to methods and compositions for treatment and prevention of disease, and in particular embodiments, disorders of the eye. In an embodiment, the present invention describes linking therapeutic compounds to xanthophyll carotenoids to enhance

FIELD OF THE INVENTION The present invention relates to quinoline derivatives and to the use thereof in therapy. More particularly, the present invention relates to quinoline derivatives for the treatment of cancer, diabetic retinopathy, age-related macular degeneration, inflammation, stroke,

FIELD OF THE INVENTION The present invention relates to quinoline derivatives and to the use thereof in therapy. More particularly, the present invention relates to quinoline derivatives for the treatment of cancer, diabetic retinopathy, age-related macular degeneration, inflammation, stroke,

The invention relates to nitrooxy derivatives of steroids, methods for their preparation, pharmaceutical compositions containing these compounds, and methods of using these compounds and compositions for treating ocular diseases, in particular diabetic macular edema, diabetic retinopathy, macular

The invention relates to nitrooxy derivatives of steroids, methods for their preparation, pharmaceutical compositions containing these compounds, and methods of using these compounds and compositions for treating ocular diseases, in particular diabetic macular edema, diabetic retinopathy, macular

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention is broadly directed to a method for inhibiting endothelial cell growth and capillary permeability associated with vascular endothelial growth factor (VEGF), e.g., the increased cell growth and permeability induced by VEGF

BACKGROUND OF THE INVENTION The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis,